May 26, 2026
Study shows Washington’s Hepatitis C plan boosted screening while cutting costs
A University of Washington–led study found that Washington state’s hepatitis C elimination initiative significantly expanded access to testing and treatment while reducing costs per patient over time.
Although total hepatitis C–related healthcare costs initially increased after the program launched in 2018, they later declined even as screening rates rose and more cases were identified. The initiative combined widespread screening, reduced barriers to care and discounted purchasing of antiviral medications, making treatment more accessible across the state.
Researchers analyzed insurance claims data covering about 70% of Washington residents from 2017 to 2022 and observed sharp increases in testing followed by declines in overall cases as treatment expanded. While total monthly costs rose early due to increased diagnosis and treatment, per‑patient costs dropped by more than 45%. The findings suggest that early detection and treatment can be both clinically effective and economically beneficial in the long run.